Skip to content

Depression: all studies

Page 133 of 1,034: studies 1,321 to 1,330 of 10,336, newest first. Back to the depression overview

Research

The Use of Ketamine for the Treatment of Anhedonia in Depression.

CNS Drugs August 1, 2024 Liliana Patarroyo-Rodriguez, Stefanie Cavalcanti, Jennifer L. Vande Voort et al. 13 citations

Anhedonia, a complex symptom rooted in deficits across reward processes, is primarily linked to depression and schizophrenia but transcends diagnostic boundaries across various mental disorders. Its presence correlates with poorer clinical outcomes, including an increased risk of suicide and diminished response to treatment. The neurobiological underpinnings of anhedonia remain incompletely...

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

European Neuropsychopharmacology August 1, 2024 Roger S McIntyre, Istvan Bitter, Jozefien Buyze et al. 30 citations

In ESCAPE-TRD (NCT04338321), esketamine nasal spray (NS) significantly increased the probability of remission at Week 8, and of being relapse-free through Week 32 after remission at Week 8, versus quetiapine extended release (XR) in patients with treatment resistant depression (TRD). Here, we explore the time course, burden and consequences of treatment emergent adverse events (TEAEs) in the...

The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) Project-Untargeted Metabolomics to Identify Biomarkers of Treatment Response to Intranasal Esketamine in Individuals with Treatment-Resistant Depression: A Study Protocol.

Alpha psychiatry August 1, 2024 Francesco Bartoli, Daniele Cavaleri, Ilaria Riboldi et al. 4 citations

Treatment-resistant depression (TRD) affects around 20-30% of people with major depressive disorder. In 2019, esketamine nasal spray was approved for TRD by both the US Food and Drug Administration and the European Medicines Agency. While its clinical efficacy and safety are proven, the mechanisms underlying its antidepressant effect remain unclear. The use of metabolomics may allow...

Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.

Journal of Psychiatric Research August 1, 2024 Noah Chisamore, Danica E. Johnson, Margery J.q. Chen et al. 21 citations

Psilocybin-assisted psychotherapy (PAP) is a promising treatment option for depression, with randomized controlled trials (RCTs) providing preliminary support for its safety and efficacy. However, there is a lack of consistency across existing treatment protocols and psychotherapeutic approaches. The objective of this review is to summarize and compare current psychotherapy methods of PAP in...

Psilocybin - A Drug to be Considered for the Treatment of Anxiety and Depression in Cancer Patients

Journal of Natural Remedies July 31, 2024 V Suresh, Jitendra Lakhani, R Balaraman

Cancer patients are more vulnerable to developing psychiatric disorders like anxiety and depression. These conditions give an additional burden leading to poor quality of life. The available antidepressant and antianxiety drugs are not very useful in improving quality of life by reducing anxiety and depressive episodes. Therefore, there is a need for good drugs to alleviate the psychiatric...

DOI: 10.18311/jnr/2024/35676 (opens in new tab) Anxiety Psilocybin Antidepressant Depression economics +6

Basic aspects of ketamine therapy for treatment-resistant depression - a review paper

Quality in Sport July 28, 2024 Weronika Szafrańska, Dominika Poborowska, Tomasz Gańko et al.

Introduction and purpose: Major depressive disorder (MDD) is the most common psychiatric illness, affecting millions of people worldwide. The first line of pharmacological treatment is usually monoamine reuptake inhibitors. Up to 60% of cases, may be drug-resistant patients, prompting researchers to research substances other than conventional. 1 The purpose of this article was to review recent...

Effects of a 4-week internet-delivered mindfulness-based cancer recovery program on anxiety, depression, and mindfulness among patients with breast cancer.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences July 28, 2024 Can Gu, Yunyun Peng, Yueyang Peng et al. 1 citation

The efficacy of monotherapy in alleviating psychological disorders like anxiety and depression among breast cancer patients is suboptimal, necessitating effective psychosocial interventions. Mindfulness-based interventions have been shown to mitigate anxiety-depression symptoms and encourage beneficial behaviors. The online mindfulness-based cancer recovery (MBCR) offers flexibility and guides...

Psychedelic experiences in psychedelic-assisted therapy for depression

Philosophical Psychology July 25, 2024 Umair Khan 1 citation

ABSTRACT Psychedelics have shown promise as a treatment for depression. Although there is some debate, a popular view is that psychedelics produce their benefits in an experience-dependent manner. This is the view that a depressed person gets better, inter alia, because of the experience she has had on psychedelics. Among the various questions that treatment for depression with psychedelics...

Effectiveness of Online Mindfulness Platform in Improving Anxiety, Depression, and Stress in Adults During the COVID-19 Pandemic: A Randomized Control Trial.

Studies in health technology and informatics July 24, 2024 Tso-Ying Lee, Cha-Jung Hsieh, Pi-Hsia Lee

COVID-19 epidemic bring a great threat to human physical and mental health. This study aimed to investigate the effectiveness of an online mindfulness platform in improving mental status. Patients from a regional hospital were randomly divided into the experimental and control groups. The experimental group received online mindfulness interventions, and control group received general health...

A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.

BMC Psychiatry July 18, 2024 Keerati Pattanaseri, Juthawadee Lortrakul, Kankamol Jaisin et al. 11 citations

Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent pain management...

DOI: 10.1186/s12888-024-05951-5 (opens in new tab) Full text (opens in new tab) Response Tolerability Depression treatment Ketamine therapy +3